Ledger. Australian venture funding, tracked

Startup · $646m raised

AdvanCell

Produces radiopharmaceuticals that target cancer cells without the typical collateral damage

Brisbane, QLD

Investors

Every investor coverage indicates participated in a round AdvanCell raised.

Investor Rounds Invested
Abingworth Series D+ · Series C -
Ally Bridge Group Series D+ -
Alpha Wave Series D+ -
Bain Capital Life Sciences Series D+ -
Brandon Capital Series D+ · Series C · Series B -
Catalio Capital Management Series D+ -
Eli Lilly Series D+ -
Eli Lilly and Company Series D+ -
Eventide Asset Management Series D+ -
Fidelity Series D+ -
Fidelity Management & Research Company Series D+ -
Morningside Series D+ · Series C · Series B -
Piper Heartland Series D+ -
Proto Axiom Series D+ -
Qatar Investment Authority (QIA) Series D+ -
Sanofi Ventures Series D+ · Series C -
SV Health Investors Series D+ · Series C -
SymBiosis Series D+ · Series C -
T. Rowe Price Series D+ -
Tenmile Series D+ · Series C -
Time BioVentures Series D+ -
Velosity Capital Series D+ -

Something wrong? Tell us